This database contains 57 studies, archived under the term: "donepezil"
Click here to filter this large number of results.
Cognitive change in donepezil treated patients with vascular or mixed dementia
Rockwood, Kenneth,
Mitnitski, Arnold,
Black, Sandra E.,
Richard, Matthew,
Defoy, Isabelle,
Vaspect study investigators
Background: vascular dementia (VaD) and mixed Alzheimer’s disease (AD/VaD) are common. How best to monitor treatment is not clear. Our objective was to compare responsiveness and construct validity of change scores, following donepezil treatment, of the standardized Mini-Mental State Examination (sMMSE) and other measures potentially usable in primary care.; Methods: A six-month, outcome measurement study. […]
Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer’s disease
Okahara, Kazunori,
Ishida, Yasushi,
Hayashi, Yoshihito,
Inoue, Teruhiko,
Tsuruta, Kazuhito,
Takeuchi, Kouzou,
Yoshimuta, Hirofumi,
Kiue, Kouichirou,
Ninomiya, Yoshimasa,
Kawano, Jiro,
Yoshida, Kensei,
Noda, Shouji,
Tomita, Seiichiro,
Fujimoto, Masumi,
Hosomi, Jun,
Mitsuyama, Yoshio
Yokukansan (YKS) is used frequently against behavioral and psychological symptoms of dementia (BPSD) together with donepezil in patients with Alzheimer’s disease (AD). Here, we investigated the efficacy and safety of YKS in patients with AD in a non-blinded, randomized, parallel-group comparison study. Patients who had at least one symptom score of four or more on […]
Donepezil improves gait performance in older adults with mild Alzheimer’s disease: A phase II clinical trial
Montero-Odasso, Manuel,
Muir-Hunter, Susan W.,
Oteng-Amoako, Afua,
Gopaul, Karen,
Islam, Anam,
Borrie, Michael,
Wells, Jennie,
Speechley, Mark
Background: Gait deficits are prevalent in people with dementia and increase their fall risk and future disability. Few treatments exist for gait impairment in Alzheimer’s disease (AD) but preliminary studies have shown that cognitive enhancers may improve gait in this population. Objective: To determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic activity, […]
Memantine versus donepezil in mild to moderate Alzheimer’s disease: a randomized trial with magnetic resonance spectroscopy
Modrego, P. J.,
Fayed, N.,
Errea, J. M.,
Rios, C.,
Pina, M. A.,
Sarasa, M.
Background and Purpose: To compare memantine with the most prescribed cholinesterase inhibitor (donepezil) from a clinical viewpoint when administered in early phases of Alzheimer disease (AD), and to find out whether memantine may produce changes in brain metabolite concentrations in comparison with donepezil.; Methods: In this comparative rater-blinded parallel group randomized trial we recruited a […]
Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008
Lazzeroni, Laura C.,
Halbauer, Joshua D.,
Ashford, J. Wesson,
Noda, Art,
Hernandez, Beatriz,
Azor, Virgina,
Hozack, Nikki,
Hasson, Noelle,
Henderson, Victor W.,
Yesavage, Jerome A.,
Tinklenberg, Jared R.
Alzheimer’s disease (AD) shortens life-expectancy, but the effects of pharmacological treatments for this disorder on mortality have not been studied. We compared two commonly prescribed medications, donepezil and memantine, with respect to the length of survival of veterans presumed to have AD. The Computerized Medical Records System at the Veterans Affairs Palo Alto Health Care […]
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
Kano, Osamu,
Ito, Hirono,
Takazawa, Takanori,
Kawase, Yuji,
Murata, Kiyoko,
Iwamoto, Konosuke,
Nagaoka, Tetsuro,
Hirayama, Takehisa,
Miura, Ken,
Nagata, Riya,
Kiyozuka, Tetsuhito,
Aoyagi, Jo,
Sato, Ryuta,
Eguchi, Teruo,
Ikeda, Ken,
Iwasaki, Yasuo
Clinical trials have shown the benefits of acetylcholinesterase inhibitors, such as donepezil and galantamine, and an N-methyl-d-aspartate receptor antagonist, memantine, in patients with Alzheimer’s disease (AD). However, little is known regarding the effects of switching from donepezil 5 mg/day to galantamine 16 or 24 mg/day, or regarding the effects of adding memantine to established therapy […]
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study
Ikeda, Manabu,
Mori, Etsuro,
Kosaka, Kenji,
Iseki, Eizo,
Hashimoto, Mamoru,
Matsukawa, Noriyuki,
Matsuo, Kazutaka,
Nakagawa, Masaki
Background/aims: To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB).; Methods: This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized, placebo-controlled trial (RCT), patients started treatment with 3 mg of donepezil daily for […]
Cilostazol add-on therapy in patients with mild dementia receiving donepezil: A retrospective study
Ihara, Masafumi,
Nishino, Madoka,
Taguchi, Akihiko,
Yamamoto, Yumi,
Hattori, Yorito,
Saito, Satoshi,
Takahashi, Yukako,
Tsuji, Masahiro,
Kasahara, Yukiko,
Takata, Yu,
Okada, Masahiro
Goal: Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in the elderly. We investigated whether the phosphodiesterase III inhibitor cilostazol, which is often used in the prevention of stroke and peripheral artery disease, may delay cognitive decline […]